SIGA Technologies, Inc. (SIGA)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$3.48+2.96%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $250M
- Forward P/E
- 3.2
- 52-week range
- $2.83 – $8.56
- 52-week change
- −59.95%
- EPS (trailing)
- −$0.04
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $94.6M (−31.82%)
- Net income
- $23.3M
- Operating margin
- 25.1%
- Diluted EPS
- $0.32
From the company’s annual report on SEC EDGAR.
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Headquarters: New York, United States · 49 employees · siga.com